RSP - On RAS drugs
(Die Seite wurde neu angelegt: „{{pnc}} {{ttp|p=32236478|t=ä. Speculation is not evidence: antihypertensive therapy and COVID-19 |pdf=|usr=}} {{tp|p=32283158|t=ä. Arterial hypertension and …“)
Zum nächsten Versionsunterschied →
Version vom 26. Mai 2020, 16:09 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
| 32236478 ä. Speculation is not evidence: antihypertensive therapy and COVID-19 |
32283158 ä. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis
32344190 ä. Debate on Drugs That May Aggravate COVID-19
32363137 ä. Anti-RAS drugs and SARS-CoV-2 infection
32370986 ä. Renin-angiotensin-aldosterone system and COVID-19 infection
32286678 2020. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19
32293003 ä. Hypertension, the renin?angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence
32215613 ä. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System?a Call for Epidemiologic Investigations
32339215 ä. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19
32332039 2020. Renin-angiotensin-aldosterone system inhibitors and COVID-19
32264922 2020. COVID-19 and the RAAS?a potential role for angiotensin II?
32213760 2020. Facts and reflections on COVID-19 and anti-hypertensives drugs
32303915 ä. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
32323279 2020. Renin-Angiotensin-System (RAS) und COVID-19 - Zur Verordnung von RAS-Blockern
32250244 2020. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
32324223 ä. Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence
32324222 ä. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19
32286607 ä. Might renin?angiotensin system blockers play a role in the COVID-19 pandemic?
32266708 ä. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
32274522 ä. Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection
32231220 ä. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
32233755 2020. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
32275190 2020. Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non?COVID-19 Sepsis but Carries a Moderately Increased Risk of Death
